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 Abstract.  A deficiency in ADAMTS13 (a von Willebrand factor [VWF] cleaving protease) is associated with accumu-
lation of prothrombogenic unusually large VWF multimers (UL-VWF) in plasma. We studied VWF release and prote-
olysis in patients with symptomatic  Plasmodium falciparum or  P. vivax malaria on the Indonesian island Sumba. Malaria 
patients had significantly lower platelet counts and higher VWF concentrations and VWF activation factors than healthy 
hospital staff controls. The latter indicates that a higher amount of circulating VWF was in a conformation enabling 
spontaneous platelet binding. In addition, ADAMTS13 activity and antigen levels were reduced in both malaria groups, 
and this was associated with the appearance of UL-VWF. The mechanism behind this reduction and the role in malaria 
pathogenesis needs to be further elucidated. In malaria, endothelial cell activation with increased circulating amounts of 
active and ultra-large VWF, together with reduced VWF inactivation by ADAMTS13, may result in intravascular platelet 
 aggregation, thrombocytopenia, and microvascular disease. 
 INTRODUCTION 
 Malaria remains an important cause of morbidity and mor-
tality in the tropics with an estimated number of 500 million 
cases and 1–3 million deaths each year. Although the exact 
pathogenesis of malaria is still incompletely understood, it 
is well known that thrombocytopenia and endothelial cell 
activation are prominent features of clinical  Plasmodium 
falciparum malaria and that platelet–endothelium interac-
tions may play an important role in its complications, such as 
cerebral malaria. 1–4 
 We have previously shown in healthy volunteers participat-
ing in an experimental human  P. falciparum infection that the 
decline in platelet numbers was associated with the onset of 
endothelial cell activation and with an increase in the amount of 
active von Willebrand factor (VWF)—i.e., the amount of VWF 
that has undergone a conformational change from a latent 
state to a state enabling spontaneous binding of platelets. 5,6 
 VWF is predominantly synthesized by endothelial cells 
and stored in specialized granules, called Weibel-Palade bod-
ies. VWF mediates platelet adhesion and aggregation at sites 
of vessel injury. Both the multimeric size and the conforma-
tion of VWF determine its activity, whereby ultra-large and 
elongated VWF multimers interact best with platelets. Under 
normal conditions, ADAMTS-13 (a disintegrin and metal-
loproteinase with thrombospondin-1-like domains) rapidly 
cleaves ultra-large and prothrombogenic VWF multimers 
(UL-VWF). 7 UL-VWF accumulation caused by absent or 
markedly reduced ADAMTS13 activity is characteristic for the 
rare microangiopathic disease thrombotic thrombocytopenic 
purpura (TTP), 8 highlighting the physiologic importance of 
ADAMTS13 cleavage of UL-VWF in humans. In recent years, 
an acquired ADAMTS13 deficiency has also been described 
in various other pathologic conditions, 9 such as sepsis and 
diffuse intravascular coagulation. 10,11 Mutations or polymor-
phisms in the  ADAMTS13 gene may also account for reduced 
plasmatic ADAMTS13 activity. A gene  polymorphism ( P475S ; 
rs11575933) that impairs ADAMTS13 activity is common in 
Japan (allelic frequency, 5.1%), 12 but rare in China (1.7%) and 
Europe (0.5%). 13,14 No other common functional polymor-
phisms have been identified thus far. 
 In our experimental human  P. falciparum malaria model in 
healthy Dutch volunteers, we found no changes in ADAMTS13 
activity levels during the pre-clinical and early clinical stages 
of malaria, when parasitemia levels were still below micros-
copy detection level. 5 However, we hypothesized that second-
ary ADAMTS13 deficiency may occur in later stages of clinical 
malaria, in which they may contribute to the development of 
thrombocytopenia and organ dysfunction, like in other sys-
temic microangiopathic diseases. 9 Moreover, although throm-
bocytopenia and organ dysfunction are also observed in 
 P. vivax malaria, 15–17 no data are available on VWF secretion 
and proteolysis in  P. vivax malaria, whereas this infection is 
highly prevalent in Asia and South America and  is responsible 
for considerable morbidity and mortality. 18 Therefore, the aim 
of this study was to determine levels of VWF, active VWF, and 
ADAMTS13 and its relation with thrombocytopenia in sub-
jects with symptomatic  P. falciparum or  P. vivax malaria on the 
Indonesian island Sumba. These levels were compared with 
those of healthy controls. Factors associated with ADAMTS13 
activity, such as the multimeric size of VWF, the presence of 
ADAMTS13 inhibitors, the relation with endothelial cell acti-
vation and inflammatory markers, and the occurrence of the 
 P475S mutation and other mutations in the  ADAMTS13 gene 
on Sumba were also studied. 
 MATERIALS AND METHODS 
 Study area, study population, and ethics.  This study was con-
ducted from April to August 2007 at the Rumah Sakit Karitas 
Hospital in Weetabula, West Sumba, East Nusa Tenggara 
Province, Indonesia, an area of unstable  P. falciparum and 
P. vivax malaria transmission. 19 Consecutive subjects pre-
senting to hospital with clinical symptoms of malaria and a 
 P.  falciparum or  P. vivax parasite density of at least 2,500 and 
500 parasites/µL, respectively, were enrolled. Healthy, asymp-
tomatic Sumbanese controls with a negative blood slide were 
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recruited among hospital staff from Weetabula, which can be 
characterized as a low malaria transmission area. In addition, 
a group of asymptomatic Sumbanese subjects with a negative 
malaria blood slide were selected from a remote village, located 
in a high malaria transmission area. To screen for the occur-
rence of common polymorphisms in the  ADAMTS13 gene in 
the Sumbanese population, DNA from 71 Sumbanese individ-
uals was used. This group consisted of villagers participating 
in a cross-section malariometric survey and of the above-
mentioned asymptomatic Sumbanese controls and the hospi-
tal staff controls. The whole  ADAMTS13 gene was sequenced 
in five subjects from this group. Healthy Dutch controls were 
recruited among laboratory staff and students. Finally, plasma 
from five Dutch TTP patients was used. Diagnostic criteria for 
TTP were the presence of thrombocytopenia with microangio-
pathic hemolysis and no detectable ADAMTS13 activity. This 
study received ethical approval for the use of human subjects 
from the Eijkman Institute for Molecular Biology Research 
Ethics Committees (Jakarta, Indonesia) and of the medical 
ethical committee of the University Medical Center Utrecht 
for use of TTP patient plasma for research purposes. All study 
participants—or parent or guardian in case of children—gave 
written informed consent to participate in this study. 
 Sample collection.  Venous blood was collected before 
administration of antimalarial drugs and/or any other treat-
ment. Blood collected in EDTA tubes (Becton-Dickinson 
Vacutainer Systems, Rutherford, NJ ) was used for deter-
mination of a full blood count; blood collected in CTAD 
tubes (Becton-Dickinson Vacutainer Systems; tubes con-
taining citrate and the platelet stabilizing agents theophyl-
line, adenosine, and dipyridamole) was used for coagulation 
and endothelial cell activation marker assays and determi-
nation of interleukin (IL)-6 concentration. Blood collected 
in heparin tubes was used for detection of anti-ADAMTS13 
autoantibodies. All samples collected in the hospital were 
centrifuged at 3,500 rpm for 10 minutes and frozen at −20°C 
until further analysis. Double centrifugation to obtain 
platelet-poor plasma is not necessary with the CTAD sys-
tem. For normal pooled plasma, platelet-depleted plasma 
of 40 healthy Dutch volunteers was pooled and stored in 
aliquots at −80°C. 
 Laboratory procedures.  Determination of parasitemia and 
full blood count.  Thick and thin blood smears were stained 
with Giemsa, and the number of parasites was quantified 
against 200 white blood cells. Parasite density was calculated 
assuming a white blood cell count of 8,000/µL. A full blood 
count was determined by a standard hematology analyzer 
(Arcus, Diatron, Vienna, Austria). 
 VWF and ADAMTS13 antigen and activity assays.  VWF 
concentrations were determined by enzyme-linked immuno-
sorbent assay (ELISA) as described previously. 20 Active VWF 
was determined by ELISA using a nanobody (AU/VWFa-11) 
that specifically recognizes the GP-1b  binding configuration 
of VWF, as described previously. 6 The multimeric pattern of 
VWF was analyzed using 2% agarose gel electrophoresis, fol-
lowed by immunoblotting according to Raines and others. 21 
ADAMTS13 activity was determined using the fluorescence 
resonance energy transfer (FRETS) assay for ADAMTS13 
activity (Peptides International, Lexington, KY ), 22 whereby the 
ADAMTS13 activity of normal pool plasma was set at 100%, 
and the values obtained in study participant samples were 
expressed as percentage of normal pool plasma. ADAMTS13 
activity was also determined by a VWF proteolysis assay as 
described  previously. 23 Briefly, proteolysis of recombinant 
VWF (IIbQ) by study participant plasma samples was com-
pared with normal pool plasma in the absence and presence 
of EDTA, which is known to inactivate ADAMTS13. In this 
assay, ADAMTS-13 activity is taken to be absent in case 
ultra-large VWF multimers remain visible after proteolysis. 
ADAMTS13 antigen levels were measured by a commercially 
available ELISA according to the instructions of the manufac-
turer (American Diagnostica, Stamford, CA). 
 ADAMTS13 inhibitors assays.  Presence of ADAMTS13 
inhibitors was determined by measuring the residual 
ADAMTS13 activity of normal pool plasma after incubation 
with plasma of study participants (volume ratio 1:1) at 37°C 
for up to 3 hours. Presence of anti-ADAMTS13 IgG anti-
bodies in plasma was measured using the Technozym inhibi-
tor ELISA (Technoclone, Vienna, Austria), according to the 
manufacturer’s instructions. In our laboratory, the upper limit 
of normal is a titer of 25 U/mL. A modification of this assay 
was used to detect the presence of IgM or IgA anti-ADAMTS 
autoantibodies. Anti-IgM and anti-IgA were added, instead 
of anti-IgG, as secondary detection antibody, and their OD 
values were compared with healthy hospital staff controls. 
 Mutations in the ADAMTS13 gene.  DNA was extracted from 
whole blood using the Chelex-100 ion exchanger (BioRad 
Laboratories, Hercules, CA). Presence of the  P475S genotype 
was determined using fluorescence-based genotyping (Assay 
on Demand; Applied Biosystems, Nieuwerkerk a/d IJssel, 
The Netherlands), as described in detail previouslye. 24 From 
five subjects, the exons of the  ADAMTS13 gene, including 
part of the intronic boundaries, were amplified by PCR on an 
ICycler PCR machine (Biorad Laboratories, Veenendaal, The 
Netherlands). Primers and PCR conditions are available on 
request. PCR products were purified using the High Pure PCR 
product purification kit (Roche Applied Science, Mannheim, 
Germany ) and sequenced in both directions using the BigDye 
Terminator kit version 3 (Applied Biosystems) and a 3730 or 
3100 DNA Analyzer (Applied Biosystems). 
 Measurement of sICAM-1 and IL-6.  Concentrations of sol-
uble intercellular adhesion molecule-1 (sICAM-1) and IL-6 
were determined by sandwich ELISA technique using anti-
human sICAM-1 (R&D DuoSet ELISA Development 
Systems) and antihuman IL-6 antibodies (ImmunoTools, 
Freiburg, Germany). 
 Statistical analysis.  Data are presented as median followed 
by interquartile range in parentheses unless otherwise stated. 
Differences between more than two groups were assessed by 
Kruskal-Wallis test for quantitative variables with the Dunn 
procedure for pairwise comparisons. Mann-Whitney  U test 
was used for comparisons between two groups. Relationships 
between laboratory parameters were assessed using the 
Pearson or Spearman correlation coefficient, depending on 
whether parameters were normally distributed. All analyses 
were performed with SPSS version 15.0 for Windows. 
 RESULTS 
 Demographic and laboratory characteristics.  Characteristics 
of the patients presenting to hospital with  P. falciparum 
malaria or  P. vivax malaria and the healthy hospital staff 
controls are shown in  Table 1 . Two patients had severe 
P.  falciparum malaria according to World Health Organization 
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criteria (hyperparasitemia). All hospital staff controls were 
adults, whereas 52% of the malaria patients were < 18 years 
of age. Thrombocytopenia was a common finding in both 
P. falciparum and  P. vivax malaria patients, and platelet num-
bers were significantly lower in the malaria patients than in 
hospital staff controls. Levels of the proinflammatory cytokine 
IL-6 and the endothelial cell activation marker sICAM-1 were 
significantly higher in both malaria groups than in hospital 
staff controls. In the malaria groups, no significant differences 
were present between children and adults in platelet number 
or in concentrations of measured mediators (data not shown). 
 VWF antigen concentrations and VWF activation factors. 
 VWF concentrations were highest in patients with  P. falci-
parum malaria ( Figure 1A ). However, compared with hospital 
staff controls, VWF concentrations in the  P. vivax group were 
also significantly elevated. The mean VWF concentration in 
hospital staff controls was comparable to the concentration 
present in normal pool plasma obtained from healthy Dutch 
volunteers (10.1 versus 12.4 µg/mL, respectively). VWF acti-
vation factors were also significantly higher in  P. falciparum 
malaria patients than in hospital staff controls ( Figure 1B ), 
indicating that their circulating VWF was in a more active 
 conformation (i.e., in a conformation enabling spontaneous 
platelet binding).  
 ADAMTS13 activity and antigen levels.  ADAMTS13 
activity levels were reduced in all patients with symptomatic
 P. falciparum or  P. vivax malaria with median (IQR) levels 
of 13.5% (9.2–23.2%) and 13.3% (9.2–19.5%), respectively 
( Figure 2A ). Levels in healthy Sumbanese hospital staff were 
comparable to levels found in healthy Dutch volunteers, 
whereas Dutch TTP patients typically had no demonstrable 
ADAMTS13 activity. ADAMTS13 antigen concentrations 
were also low in nearly all malaria patients ( Figure 2B ), and 
concentrations correlated well with ADAMTS13 activity lev-
els (Pearson  R = 0.78;  P < 0.001). Additionally, the findings of 
low plasmatic ADAMTS13 activity by the FRETS assay were 
confirmed in a proteolytic VWF multimer assay.  Figure 3A 
shows the results of this assay for three patients with a mod-
erate decrease in ADAMTS13 activity and one with severely 
reduced activity (4%). Especially in the latter, large VWF mul-
timers remained visible after incubation of synthetic VWF with 
patient plasma, confirming a strong reduction of plasmatic 
ADAMTS13 activity. Further confirmation was obtained by 
analysis of the VWF multimer pattern in plasma of malaria 
patients. As shown for two patients with  P. falciparum in 
 Figure 3B , UL-VWF could be detected in the plasma of these 
patients. Finally, we determined ADAMTS13 activity and anti-
gen levels in Sumbanese with a negative malaria slide, living in 
remote villages, and found very low ADAMTS13 activity and 
antigen levels. Compared with the hospital staff controls, these 
villagers had significantly lower platelet counts (222 versus 331 
 FIGURE 1.  Scatter dot plots with line at median showing VWF anti-
gen concentrations ( A ) and VWF activation factors ( B ) in patients with 
symptomatic  P. falciparum malaria ( N = 26),  P. vivax malaria ( N = 16), 
and healthy Sumbanese hospital staff controls ( N = 11). Group 
comparisons were done using Kruskal-Wallis test, whereas pair-
wise comparisons were done using the Dunn procedure (* P < 0.05; 
** P < 0.001;  ns P > 0.05). 
 FIGURE 2.  Scatter dot plots with line at median showing ADAMTS13 
activity ( A ) and ADAMTS13 antigen concentrations ( B ) in patients 
with symptomatic  P. falciparum malaria ( N = 26),  P. vivax malaria 
( N = 16), healthy Sumbanese hospital staff controls ( N = 11), healthy 
Dutch controls ( N = 9), and thrombotic thrombocytopenic purpura 
(TTP) patients ( N = 5). ADAMTS13 activity is expressed as percent-
age of normal pool plasma. Group comparisons were done using 
Kruskal-Wallis test, whereas pairwise comparisons were done using 
the Dunn procedure (* P < 0.05; ** P < 0.001;  ns P > 0.05). 
 TABLE 1 
 Demographic and laboratory characteristics of study participants 
 P. falciparum malaria  P. vivax malaria Hospital staff controls P
Number of subjects ( N )  26  16  11
Sex (% female)  50.0  50.0  90.9
Age (years)  20.0 (3.8–37.3)  11.0 (2.1–25.3)  25.5 (21.2–30.8) 0.066*
Parasitemia (parasites/µL) 3,240 (2,420–8,200)   880 (800–1,240)  0 < 0.001†
Hemoglobin level (g/dL)  9.3 (7.9–12.2)  11.6 (9.9–13.2)  13.2 (11.3–13.4) 0.009*‡
Platelet count (×10 9 /L)   122 (70–154)   117 (77–220)   237 (172–258) < 0.002*‡§
Thrombocytopenia (%)¶  69.2  50.0  9.1
White blood cell count (×10 9 /L)  6.3 (5.0–8.0)  7.6 (6.2–8.6)  7.7 (6.6–9.4) 0.114*
Lymphocytes (×10 9 /L)  0.9 (0.6–1.7)  1.8 (1.4–3.7)  2.1 (1.9–2.7) 0.001*‡
Granulocytes (×10 9 /L)   4.4 (3.4–6.3)  4.3 (3.4–5.8)  4.0 (3.6–5.6) 0.985*
Interleukin-6 (pg/mL)  28.1 (2.0–87.5)  9.2 (2.0–45.6)    NA** 0.659†
sICAM-1 (pg/mL) 245.7 (213.7–283.4) 190.5 (141.8–402.5) 123.3 (94.6–140.4) < 0.001*‡§
 Data are median (interquartile range) unless otherwise specified.  NA , not applicable; sICAM-1, soluble intercellular adhesion molecule-1.
 *  Differences between three groups by Kruskal-Wallis test, with post hoc testing by the Dunn procedure. 
† Mann-Whitney  U test.
‡  P < 0.05 between  P. falciparum and control group. 
§  P < 0.05 between  P. vivax and control group.
 ¶ Thrombocytopenia defined as platelet number < 150 × 10 9 /L. 
**  Below assay’s detection limit in all. 
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× 10 9 /L;  P = 0.012) and borderline significantly higher VWF 
concentrations (15.3 versus 10.1 µg/mL;  P = 0.07). However, 
although the differences in platelet number and VWF concen-
tration might indicate that the low ADAMTS13 levels were a 
true finding, we decided to exclude these samples from further 
analysis because heat inactivation of ADAMTS13 during sam-
ple collection or transport to hospital could not be excluded 
with certainty.  
 ADAMTS13 inhibitors and mutations in the  ADAMTS13 
gene.  In six malaria patients with strongly reduced ADAMTS13 
activity levels, we determined the presence of ADAMTS13 
inhibitors and ADAMTS13 autoantibodies. There was no 
 difference in decline in residual ADAMTS13 activity between 
a mixture of normal pool plasma incubated with patient plasma 
and normal pool plasma alone (data not shown). In addition, no 
increased titers of ADAMTS13 autoantibodies of the IgG, IgA, 
or IgM class were found (data not shown). Because mutations in 
the  ADAMTS13 gene may also influence ADAMTS13 activity 
and antigen levels in the Sumbanese population, we screened a 
group of 71 Sumbanese for the presence of the  P475S polymor-
phism, which is common in Japan. 12 This mutation was, how-
ever, not found in any of these subjects. Subsequent sequencing 
of the  ADAMTS13 gene of five Sumbanese to screen for the 
occurrence of other common polymorphisms yielded multiple 
silent exonic mutations in all five Sumbanese and one missense 
mutation in one subject ( Table 2 ). The silent mutations have 
all been previously reported as single nucleotide polymor-
phisms (SNPs), 25 whereas the missense mutation has not been 
described before. However, although the silent mutations were 
highly prevalent in the remaining 66 Sumbanese, including 
our hospital staff controls with normal ADAMTS13 levels, the 
missense mutation was not found in others. Unfortunately, 
no ADAMTS13 level was available for the subject with the 
missense mutation.  
 Correlations between laboratory parameters.  Figure 4 
depicts correlations between VWF activation factor, platelet 
count, and ADAMTS13 activity and antigen concentrations 
in patients with  P. falciparum or  P. vivax infection. Higher 
VWF activation factors were associated with lower platelet 
counts ( Figure 4A ). Furthermore, ADAMTS13 antigen con-
centrations, but not ADAMTS13 activity levels, were inversely 
correlated with VWF activation factors ( Figure 4B and C). 
ADAMTS13 antigen and VWF antigen concentrations were 
also inversely associated (Spearman  R = −0.413;  P = 0.007). 
Finally, there was an inverse correlation of IL-6 concentra-
tions with ADAMTS13 activity levels (Spearman  R = −0.417; 
 P = 0.007) and with platelet count (Spearman  R = −0.442; 
P = 0.006). No significant correlation was present between 
platelet numbers and either ADAMTS13 activity levels 
(Spearman  R = 0.081;  P = 0.626) or ADAMTS13 antigen con-
centrations (Spearman  R = 0.273;  P = 0.097).  
 DISCUSSION 
 In this study, we reported that symptomatic  P. falciparum or 
 P. vivax infections are associated with a significant increase in 
VWF and active VWF levels and a decrease in ADAMTS13 
activity and antigen levels, resulting in the presence of circulat-
ing UL-VWF multimers. 
 The high VWF activation factors with circulating UL-VWF 
multimers indicated that an increased amount of the circu-
lating VWF was in an active platelet binding conformation, 
which was supported by our findings of an inverse  correlation 
between platelet numbers and VWF activation factors. We 
have previously found a similar association in our experimen-
tal human  P. falciparum malaria model, 5 and our current study 
expands these observations to naturally acquired  P. falciparum 
and  P. vivax infections. Both sICAM-1 and VWF are known 
 TABLE 2 
 Mutations in the  ADAMTS13 gene identified in five Sumbanese individuals with the prevalence in 66 other Sumbanese individuals 
Subject Exon Nucleotide Amino acid
Prevalence in 66 Sumbanese individuals
WT Het Ho
1 + 2 + 4 + 5 5   420  T  > C Silent 6% 31% 63%
1 + 2 + 3 + 4 + 5 15 1716 G > A Silent 7% 36% 58%
1 + 2 + 4 + 5 19 2280 C > T Silent 25% 23% 51%
4 29 4221 C > A Silent ND
3 22 2814 G > T K938N 100%  0%  0%
 WT = wildtype; Het = heterozygous; Ho = homozygous; ND= not determined. 
 FIGURE 3.  A , VWF proteolysis assay showing multimeric pattern of 
recombinant IIbQ VWF after incubation with plasma from individual 
 P. vivax and  P. falciparum patients with moderate or severely reduced 
ADAMTS13 activity in FRETS assay and with normal pool plasma 
in absence and presence of EDTA (inactivator of ADAMTS13 activ-
ity). Percentages in parentheses indicate the ADAMTS13 activity in 
the plasma of the individual patients using FRETS assay. ADAMTS13 
deficiency is shown by the presence of large VWF multimers.  B , VWF 
multimer pattern in the plasma of two patients with  P. falciparum 
malaria with reduced ADAMTS13 activity (14% and 15%, respec-
tively), showing presence of circulating ultra-large VWF multimers 
(multimers visible above the dashed line). NPP depicts normal pooled 
plasma of healthy Dutch subjects. 
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markers of endothelial cell perturbation, and these findings 
therefore suggest that endothelial cell perturbation is not 
a phenomenon restricted to  P. falciparum but also occurs in 
P. vivax malaria, an infection in which thrombocytopenia is 
also a common observation. 15 This is in line with a previous 
study, which also found an almost similar increase in sICAM-1 
concentrations in patients with either  P. vivax or uncompli-
cated  P. falciparum malaria. 26 We speculate that, in addition 
to providing a mechanistic explanation for the thrombocy-
topenia in  P. vivax malaria, relapsing  P. vivax blood infections, 
which arise from dormant liver stages, may induce repeated 
episodes of endothelial cell activation with excessive VWF 
release. In high-income countries, elevated VWF levels have 
been associated with adverse clinical consequences, such as 
increased risk for cardiovascular diseases. 27 However, the pos-
sible clinical consequences of high VWF levels and decreased 
ADAMTS13 activity need to be determined for low-income 
countries where malaria is endemic. 
 Recent evidence suggests that severe disturbances in the 
interplay of endothelial cells, platelets, VWF, and ADAMTS13 
may result in secondary microangiopathy and thrombocytope-
nia-associated multi-organ failure in severely ill patients. 28–30 
Our study included patients with symptomatic, but uncom-
plicated  P. falciparum or  P. vivax malaria. Although the 
occurrence of microvascular dysfunction was not routinely 
classified, the alterations in the balance between VWF secre-
tion and ADAMTS13 activity in our patients probably did not 
seem to result in clinically relevant complications. However, 
at this moment, we cannot exclude with certainty that more 
severe disturbances in the VWF/ADAMTS13 system may 
contribute to the development of complications in severe 
malaria, as reported for severe sepsis. Future studies are 
needed in patients with severe malaria to test this hypothesis, 
as well as studies determining the functional threshold levels 
of ADAMTS13 activity below which complications may ensue. 
In addition, recent data have proposed a role for angiopoi-
etin-2 in the pathogenesis of severe falciparum malaria. 31 Both 
angiopoietin-2 and VWF are constituents of endothelial cell 
Weibel-Palade bodies, highlighting the possible importance of 
Weibel-Palade body exocytosis in malaria pathogenesis. 
 At this time, the exact pathogenic mechanism behind the 
low ADAMTS13 activity levels in our malaria patients remains 
elusive. Induction of ADAMTS13 autoantibodies is the usual 
underlying pathogenic mechanism in TTP. Malaria may also 
induce various autoantibodies, as suggested by their high prev-
alence in malaria-endemic regions. 32 However, inhibitor assays 
could not show the presence of inhibitors or ADAMTS13 
autoantibodies in our study population, although the used 
assays may not have been sufficiently sensitive to detect weak 
inhibitors or low ADAMTS13 autoantibody titers. 
 Alternatively, various non-immune mechanisms may be 
involved. First, consumption of ADAMTS13 is observed 
in situations with release of large amounts of VWF, as pre-
viously shown by desmopressin or endotoxin administra-
tion, 33,34 whereas the proinflammatory cytokine IL-6 at high 
concentrations can inhibit, at least partially, ADAMTS13 
activity. 35 In our study, VWF and IL-6 concentrations indeed 
correlated inversely with ADAMTS13 antigen concentrations. 
Regrettably, the limited sample size of our study did not allow 
a multivariate analysis. Second, parasites express various pro-
teases, and these might theoretically inactivate ADAMTS13, 
as has recently been shown for the bacterium  Bacillus anthra-
cis . 36 ADAMTS13 activity levels were, however, equally low 
in patients with  P. falciparum and  P. vivax malaria, despite the 
parasite density being much lower in vivax malaria. Third, high 
concentrations of free hemoglobin, 37 as can be found in mas-
sive intravascular hemolysis or  in vitro hemolysis, and of the 
 coagulation proteins plasmin and thrombin have been reported 
to reduce ADAMTS13 activity. 38 However, none of the plasma 
samples in our study were macroscopically hemolytic and 
a marked procoagulant state with diffuse intravascular coag-
ulation is rare in malaria. 39 Fourth, reduced ADAMTS13 
 FIGURE 4 .  Correlation of VWF activation factor with platelet 
count ( A ), ADAMTS13 activity levels ( B ), and ADAMTS13 anti-
gen concentrations ( C ) in patients with symptomatic  P. falciparum 
( N = 26) or  P. vivax ( N = 16) malaria. Shown is the Spearman correla-
tion coefficient. 
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synthesis by liver stellate cells and/or endothelial cells may 
also result in ADAMTS13 deficiency. Recently, inflamma-
tory cytokines were shown to reduce ADAMTS13 synthesis  in 
vitro . 40 Finally, genetic mutations may influence ADAMTS13 
activity and antigen levels, and malaria may have resulted 
in selection of certain polymorphisms in malaria-endemic 
regions. However, the  P475S polymorphism, which is common 
in Japan, was not found in 71 Sumbanese individuals. In addi-
tion, sequencing of the  ADAMTS13 gene in a small number of 
Sumbanese subjects did show three highly prevalent SNPs, but 
these were also present in hospital staff controls with normal 
ADAMTS13 activity and antigen levels, suggesting that these 
SNPs are not associated with altered ADAMTS13 expression. 
 In conclusion, we showed that symptomatic  P. falciparum 
and  P. vivax infections are associated with endothelial cell 
perturbation, ADAMTS13 deficiency, and increased con-
centrations of active and ultra-large VWF. These combined 
mechanisms may contribute to malaria-induced thrombocy-
topenia. Future studies are needed to determine whether the 
disturbances in the interplay between endothelial cells, VWF, 
ADAMTS13, and platelets may also play a role in the compli-
cations observed in severe malaria. 
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